NCT07125508View on ClinicalTrials.gov

Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 1, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

December 15, 2024

Conditions
AnemiaSmall Bowel BleedingAngioectasias
Interventions
DRUG

Tranexamic Acid (TXA) treatment

Patients randomized to the interventional arm will take oral tranexamic acid 650 mg three times per day for 3 months. They will have blood work drawn every month for the 3 month trial period.

DRUG

Placebo

Placebo intervention

Trial Locations (1)

70112

LSU Health Sciences Center - New Orleans, New Orleans

All Listed Sponsors
lead

Louisiana State University Health Sciences Center in New Orleans

OTHER